Biotechnology
Price
$116.86
+2.68%Market Cap
$23.35B
Day High
$118.69
Day Low
$113.50
Incyte Corporation delivered a strong Q1 FY2026, with revenue surging 20.9% YoY to $1.27B and net income nearly doubling to $303.3M, driven by robust product sales and disciplined cost management.
Key risk: High R&D Spending Relative to Revenue
R&D expenses of $515.9M represent approximately 40.5% of Q1 FY2026 revenue, a level that could pressure profitability if pipeline assets fail to advance or receive regulatory approval. Clinical-stage failures could result in significant write-offs with no corresponding revenue benefit.
Other Biotechnology companies